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Background: Cancers, a group of multifactorial complex diseases, are generally caused by mutation of multiple
genes or dysregulation of pathways. Identifying biomarkers that can characterize cancers would help to understand
and diagnose cancers. Traditional computational methods that detect genes differentially expressed between
cancer and normal samples fail to work due to small sample size and independent assumption among genes. On
the other hand, genes work in concert to perform their functions. Therefore, it is expected that dysregulated
pathways will serve as better biomarkers compared with single genes.
Results: In this paper, we propose a novel approach to identify dysregulated pathways in cancer based on a
pathway interaction network. Our contribution is three-fold. Firstly, we present a new method to construct pathway
interaction network based on gene expression, protein-protein interactions and cellular pathways. Secondly, the
identification of dysregulated pathways in cancer is treated as a feature selection problem, which is biologically
reasonable and easy to interpret. Thirdly, the dysregulated pathways are identified as subnetworks from the
pathway interaction networks, where the subnetworks characterize very well the functional dependency or crosstalk
between pathways. The benchmarking results on several distinct cancer datasets demonstrate that our method can
obtain more reliable and accurate results compared with existing state of the art methods. Further functional
analysis and independent literature evidence also confirm that our identified potential pathogenic pathways are
biologically reasonable, indicating the effectiveness of our method.
Conclusions: Dysregulated pathways can serve as better biomarkers compared with single genes. In this work, by
utilizing pathway interaction networks and gene expression data, we propose a novel approach that effectively
identifies dysregulated pathways, which can not only be used as biomarkers to diagnose cancers but also serve as
potential drug targets in the future.Background
Cancer is a type of complex diseases, which generally
involves multiple gene mutations and pathway dysregu-
lations [1,2]. Identifying biomarkers for cancer can help
to understand and diagnose diseases, which in turn helps
to design drugs with effective therapy. However, it is a
challenging task to detect reliable biomarkers in cancers.
Recently, the accumulation of large amount of “omics”
data in public databases provides an opportunity for
detecting biomarkers, among which the gene expression
data are widely used. Accordingly, much effort has been* Correspondence: hao@info.univ-angers.fr; lnchen@sibs.ac.cn;
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reproduction in any medium, provided the ormade to identify causal disease genes based on these
data. For example, many computational methods have
been developed to detect differentially expressed genes
between normal and disease samples [3–5], and these
genes are supposed to be related to diseases and can be
used as biomarkers. Unfortunately, many of the differen-
tially expressed genes detected in one dataset are later
found not to work effectively in another dataset for the
same disease, especially for complex diseases [6]. This
phenomenon may arise due to the independency as-
sumption among disease related genes when detecting
differentially expressed genes, whereas complex diseases
are generally caused by the dysregulation of functional
modules that consist of a set of genes [7–9].
Due to the poor performance of biomarkers as differ-
entially expressed genes, some approaches have been. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.








GSE 4115 Lung Cancer 187 (97/90) GPL96 (HG-U133A)
GSE 6919 Prostate Tumour 128 (65/63) GPL8300 (HG_U95Av2)
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which improves the robustness and accuracy when
these pathways are used as biomarkers compared with
above mentioned gene based methods [10–18]. For ex-
ample, Lee et al. [13] proposed to use a subset of
genes belonging to one pathway as biomarkers to ac-
curately distinguish diseases from controls. Liu et al.
[18] used pathways to compare different regions of
Alzheimer's disease brains and found dysfunctional
pathways that cooperate in different brain regions. Des-
pite the success of these methods on some datasets,
the majority of them do not consider the functional de-
pendency between pathways. Generally, different path-
ways have crosstalk with each other, and the
deregulation of one pathway may affect the activities of
many related pathways. Therefore, it is possible to de-
tect more reliable pathway biomarkers by taking into
account the functional dependency or interaction be-
tween pathways.
In this paper, we propose a novel method to identify
dysregulated pathways by considering pathway interac-
tions. The identified dysregulated pathways can be
used as candidate biomarkers to diagnose cancer. Spe-
cifically, a new approach is proposed to construct a
pathway interaction network, which describes the func-
tional dependency between pathways. Subsequently, the
dysregulated pathways in cancer are identified as the
best features to discriminate cancers from controls in
a machine learning framework. Benchmarking our
method on several distinct cancer datasets shows that
our method outperforms previous state of the art
methods. Furthermore, functional analysis and inde-
pendent experimental evidence demonstrate that our
identified dysregulated pathways are biologically rea-





The gene expression datasets were obtained from the
NCBI Gene Expression Omnibus (GEO) [19]. We chose
four different types of cancer datasets that have
balanced number of disease and control samples in
each dataset. Table 1 lists the gene expression datasets
that were used in this work, including lung cancer
(GSE4115) [20], prostate tumour (GSE6919) [21], breast
cancer (GSE15852) [22], and pancreatic tumour
(GSE16515) [23]. For each gene expression dataset, the
annotations for probes were obtained from GEO and
each probe was mapped to a gene, where the probes
were discarded if they do not match any gene. The ex-
pression value averaged over probes was used as the
gene expression value if the gene has multiple probes.Subsequently, the expression values of all genes in each
dataset were standardized as follows
zij ¼ gij mean gið Þstd gið Þ ð1Þ
where gij represents the expression value of gene i in
sample j, and mean(gi) and std(gi) respectively repre-
sents mean and standard deviation of the expression
vector for gene i across all samples.
Cellular pathways and human protein-protein interactions
The predefined biological pathways were obtained from
the Molecular Signatures Database (MSigDB) [24],
which is a large collection of annotated functional gene
sets. We chose the canonical pathways in the curated
gene sets that contain 880 pathways, including the meta-
bolic and signaling pathways collected from BioCarta
(www.biocarta.com), KEGG [25], and Reactome [26].
The human protein-protein interactions (PPIs) were
obtained from the Human Protein Reference Database
(HPRD, downloaded in February 2010) [27], which con-
tains manually curated protein-protein interactions. The
PPI data set contains 38788 protein interactions among
9630 unique human proteins.
Pathway activity and pathway interaction network
Figure 1 illustrates the flowchart of our proposed
method. Firstly, the pathway activity was defined based
on gene expression data for each pathway. Secondly, a
pathway interaction network (PIN) was constructed
based on pathways and PPIs for each dataset. Thirdly,
the dysregulated pathways in cancer are identified from
PIN. The details were addressed as follows.
Pathway activity
All the genes were mapped to pathways extracted from
MsigDB and only those genes that can be mapped to
pathways were kept for further analysis hereinafter. After
the genes were mapped to pathways, we defined an ac-
tivity score for each pathway as the summary of the ex-
pression values of all genes belonging to this pathway. In
particular, we used principal component analysis (PCA)
method [28] to get the summary of all gene expressions
Figure 1 Schematic illustration of identifying dysregulated pathway in cancer. Firstly, gene expression profiles were standardized. Secondly,
the genes were mapped to pathways. For each pathway, the principal component analysis (PCA) was employed to calculate the pathway activity
score that summarizes the expression values of genes in each pathway. Thirdly, the pathway interaction network (PIN) was constructed based on
gene expression data, protein-protein interactions, and cellular pathways. In the PIN, each node represents a pathway while each edge denotes
the functional association between two pathways. Fourthly, the dysregulated pathways were identified as pathway markers that can best
distinguish diseases from controls. The red node in PIN is the firstly identified pathway marker in disease, and the yellow ones are those pathway
markers that can be combined with the first selected pathway to obtain best classification results while discriminating between diseases and
controls.
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characterize the internal structure of high-dimension
dataset by preserving the variance in the data while
transforming the data into low-dimension space. In brief,
the activity score Pkj of pathway k in sample j was
defined as follows.
Pkj ¼ w1jkz1jk þ w2jkz2jk⋯þ wijkzijk ð2Þ
where zijk represents the standardized expression value
of gene i from pathway k in sample j, and wijk denotes
weight for zijk. In other words, the activity of each path-
way can be regarded as the linear combination of the
expressions of all genes in the pathway, and each path-
way can be regarded as a meta-gene. In particular, the
first principal component from PCA was used as theactivity score for the corresponding pathway here.
Therefore, the pathways that have different activities in
diseases between controls are possibly related to
diseases.
Pathway interaction network (PIN)
A pathway interaction network (PIN) was constructed
with each node representing a pathway, where one edge
was laid between two pathways if they share at least one
gene or there are interactions between genes from the
two pathways based on PPIs. Due to the condition-
specificity of gene expression and pathway activity, for a
given gene expression dataset, we further required that
at least one of the common genes between two pathways
is differentially expressed (student’s t-test, p-value< 0.05)
between diseases and controls, or the two genes that










GSE 4115 867 43021 5371
GSE 6919 867 33123 4429
GSE 15852 866 40632 5325
GSE 16515 880 53397 6152
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between two pathways are highly co-expressed (Pear-
son’s correlation coefficient, absolute value> 0.8).Figure 2 Results obtained by PIN, PAC, BMI and gene biomarkers on
biomarkers on four cancer datasets, where PIN, PAC, BMI and Gene respect
biomarkers and gene biomarkers. (A). Lung cancer dataset, where PIN gets
by Gene. (B). Prostate tumour dataset, where PIN gets AUC score of 0.82 co
tumour dataset, where PIN gets AUC score of 0.99 compared with 0.92 by
where PIN gets AUC score of 0.98 compared with 0.90 by PAC, 0.84 by BMOtherwise, the edge between two pathways will be
removed. Therefore, a pathway interaction network was
constructed for each dataset. The number of pathways
and corresponding interactions in each PIN built for
each dataset were shown in Table 2.
Identifying dysregulated pathways from pathway
interaction network
After defining the activity score for each pathway, we
formulated the identification of dysregulated pathways
as a feature selection problem in a machine learning
framework, where the minimum set of pathways that
can best discriminate diseases from controls werefour cancer datasets. Results obtained by PIN, PAC, BMI and gene
ively denotes our pathway biomarkers, PAC biomarkers, BMI
AUC score of 0.82 compared with 0.70 by PAC, 0.76 by BMI and 0.73
mpared with 0.71 by PAC, 0.77 by BMI and 0.63 by Gene. (C). Breast
PAC, 0.93 by BMI and 0.90 by Gene. (D). Pancreatic tumour dataset,
I and 0.90 by Gene.
Table 3 Dysregulated pathways identified in lung cancer (GSE4115) dataset
Pathway Description Number of genes
REACTOME_SPHINGOLIPID_METABOLISM Genes involved in sphingolipid metabolism 32
REACTOME_TRIACYLGLYCERIDE_BIOSYNTHESIS Genes involved in triacylglyceride biosynthesis 14
KEGG_PPAR_SIGNALING_PATHWAY PPAR signaling pathway 69
REACTOME_AKT_PHOSPHORYLATES_TARGETS_IN_THE_CYTOSOL Genes involved in AKT phosphorylates targets
in the cytosol
14
REACTOME_TCR_SIGNALING Genes involved in TCR signaling 64
BIOCARTA_STATHMIN_PATHWAY Stathmin and breast cancer resistance to
antimicrotubule agents
19
ST_T_CELL_SIGNAL_TRANSDUCTION T Cell signal transduction 44
BIOCARTA_SPRY_PATHWAY Sprouty regulation of tyrosine kinase signals 18
ST_IL_13_PATHWAY Interleukin 13 (IL-13) Pathway 7
BIOCARTA_INTEGRIN_PATHWAY Integrin signaling pathway 38
BIOCARTA_CELL2CELL_PATHWAY Cell to cell adhesion signaling 14
REACTOME_APOPTOTIC_CLEAVAGE_OF_CELL_ADHESION_PROTEINS Genes involved in apoptotic cleavage of cell
adhesion proteins
11
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It is reasonable and biologically interpretable to con-
sider dysregulated pathways as discriminative features.
In detail, a single pathway that can best discriminate
between diseases and controls was firstly identified as
the first pathway biomarker, and the second pathway
that can be combined with the first pathway to get bet-
ter classification results was identified from those path-
ways that interact with the first pathway in PIN. This
procedure was repeated to add new pathways to
selected pathway biomarkers until no more pathways
can be added to improve classification accuracy, and
the final selected pathway biomarkers were retained as
potential dysregulated pathways in diseases. In feature
selection, we used support vector machines (SVMs),
which is a widely used kernel based method especially
useful for small number of samples with high dimen-
sional variables. In this work, the LIBSVM [29] toolbox
was used with radial basis functional (RBF) kernel. The
performance of the classifier was evaluated with five-
fold cross validation, and AUC (Area Under ROC
Curve) score was adopted as classification performance
index. In the five-fold cross validation, all samples were
randomly split into five equal-size subsets without over-
lap, four of which were used as training set while the





KEGG_TRYPTOPHAN_METABOLISM Tryptperformance. To get robust results, we repeated five-
fold cross-validation for 100 times and the average was
used as the final result in each dataset.
Results
Identification of dysregulated pathways in cancer
To evaluate our method, we applied it to identify dysre-
gulated pathways for the four cancer datasets listed in
Table 1. Moreover, we used these pathways to discrim-
inate diseases from controls and compared our results
with two classical differentially expressed gene detection
methods, including the student’s t-test and Biomarker
identifier (BMI) method [30,31]. In the BMI method,
the differentially expressed genes were ranked by logis-
tic regression analysis (LRA), and this method was
shown to outperform other methods. The genes
selected by student’s t-test and BMI were respectively
denoted as gene biomarkers and BMI biomarkers here-
inafter. For comparison with student’s t-test and BMI,
we picked the same number of top ranked genes by
these two methods as that of our selected pathways.
Figure 2 shows the results obtained by gene biomarkers
and BMI biomarkers compared with our method
(denoted as PIN biomarkers). The dysregulated path-
ways identified by our method in four cancer datasets
were respectively listed in Tables 3, 4, 5, 6. We can(GSE6919) dataset
ription Number of genes
s involved in metablism of nucleotides 71
s involved in purine metabolism 30
inate and nicotinamide metabolism 24
ophan metabolism 40
Table 5 Dysregulated pathways identified in breast tumour (GSE15852) dataset
Pathway Description Number of genes
KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY Adipocytokine signaling pathway 67
REACTOME_TCR_SIGNALING Genes involved in TCR signaling 64
REACTOME_P75NTR_SIGNALS_VIA_NFKB Genes involved in p75NTR signals via NF-κB 13
BIOCARTA_ATM_PATHWAY ATM signaling pathway 20
REACTOME_ACTIVATION_OF_THE_AP1_FAMILY_OF_TRANSCRIPTION_FACTORS Genes involved in activation of the AP-1 family
of transcription factors
10
KEGG_INSULIN_SIGNALING_PATHWAY Insulin signaling pathway 137
BIOCARTA_AKAP13_PATHWAY Rho-Selective guanine exchange factor AKAP13
mediates stress fiber formation
12
BIOCARTA_CK1_PATHWAY Regulation of ck1/cdk5 by type 1 glutamate
receptors
17
KEGG_PANCREATIC_CANCER Pancreatic cancer 70
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forms the other two methods on all four different can-
cer datasets, indicating the effectiveness and efficiency
of our proposed method. For example, for lung cancer
dataset, our method performed very well with an AUC
score of 0.82 compared against gene biomarker with an
AUC score of 0.71 and BMI biomarker with an AUC
score of 0.70. Except for the AUC score, we also com-
pared the four methods with respect to accuracy, sensi-
tivity and specificity (detailed results can be found in
Additional file 1: Table S1). The promising results
obtained by the proposed method also demonstrate that
our identified pathway biomarkers are potential dysre-
gulated pathways in cancer.
Moreover, we also compared our method with one
state of the art dysregulation pathway identification
method, i.e., PAC (Pathway Activity inference using
Condition-responsive gene activity) method, proposed
by Lee et al. [13]. In the PAC method, the pathway activ-
ity was defined as a combined score of a subset of genes,
called the condition-responsive genes, that yields the
best discriminative score. The pathways with different
discriminative power were subsequently ranked based




KEGG_P53_SIGNALING_PATHWAY P53 signaling pathway 69
ST_JNK_MAPK_PATHWAY JNK MAPK pathway 38
ST_P38_MAPK_PATHWAY P38 MAPK pathway 35
BIOCARTA_SALMONELLA_PATHWAY Salmonella pathway 13
BIOCARTA_CDC42RAC_PATHWAY Role of PI3K subunit
p85 in regulation of
actin organization and
cell migration
16cancer datasets. For a fair comparison, we used the same
SVM toolbox and the same number of pathways identi-
fied by our method. The results of the PAC method
(denoted as PAC biomarkers) were also shown in Fig-
ure 2 (detailed results can be found in Additional file 1:
Table S1). As shown in Figure 2, our proposed method
achieved a higher AUC score than the PAC method on
all four datasets. These results indicate that our pro-
posed approach helps to improve the discriminative
power by taking into account the functional dependency
between pathways.
Furthermore, we compared the genes involved in our
identified dysregulated pathways with those top ranked
differentially expressed genes. Table 7 lists the numbers
of genes involved in both our identified dysregulated
pathways and those top ranked differentially expressed
genes (the same number of genes as those in dysregu-
lated pathways). It is found that only a small fraction
(from 2.8% to 8.4%) of the genes in our identified dysre-
gulated pathways overlaps with top ranked differentially
expressed genes. This phenomenon implies that a path-
way as an entity can better diagnose complex diseases
rather than individual genes even though the genes in
the pathway are not differentially expressed significantly.Table 7 The overlap between the genes in dysregulated
pathways and gene biomarkers, where the two sets have












GSE 4115 255 9 3.5%
GSE 8397 94 5 5.3%
GSE 15852 285 24 8.4%
GSE 16515 142 4 2.8%






GSE 2514 39 (19/20) GPL8300 (HG_U95Av2)
GSE 7670 54 (27/27) GPL96 (HG-U133A)
GSE 10072 107 (49/57) GPL96 (HG-U133A)
GSE 19027 51 (30/21) GPL96 (HG-U133A)
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To further test our method, we applied the identified dys-
regulated pathways from above lung cancer dataset (GSEFigure 3 Results obtained by PIN, PAC, BMI and gene biomarkers on
cancer dataset (GSE 4115) by four methods were applied to independent l
where PIN, PAC, BMI and Gene respectively denotes our pathway biomarke
dataset, where PIN gets AUC score of 0.99 compared with 0.99 by PAC, 0.9
score of 0.99 compared with 0.99 by PAC, 0.80 by BMI and 0.85 by Gene. (C
0.99 by PAC, 0.93 by BMI and 0.96 by Gene. (D). GSE19027 dataset, where P
and 0.52 by Gene.4115, see Table 3) to other four independent hold-out
datasets of lung cancer (GSE2514 [32], GSE7670 [33],
GSE10072 [34] and GSE19027 [35]) that are from two dif-
ferent Affymetrix platforms, i.e., GPL8300 (HG_U95Av2)
and GPL96 (HG-U133A). Note that all of these test data-
sets list in Table 8 are not used in above section, thereby
evaluating our proposed method in an objective way.
Similarly, the gene or pathway biomarkers selected from
GSE4115 dataset by other methods were also applied to
the four lung cancer test datasets. The same numbers of
pathways or genes as that of our selected pathways were
chosen for a fair comparison. The pathway biomarkersfour lung cancer datasets. The biomarkers identified from lung
ung cancer test datasets (GSE7670, GSE10072, GSE19027, and GSE2514),
rs, PAC biomarkers, BMI biomarkers and gene biomarkers. (A). GSE2514
5 by BMI and 0.87 by Gene. (B). GSE7670 dataset, where PIN gets AUC
). GSE10072 dataset, where PIN gets AUC score of 0.99 compared with
IN gets AUC score of 0.71 compared with 0.63 by PAC, 0.65 by BMI
Figure 4 Dysregulated pathways interaction network in
pancreatic tumour dataset. In pancreatic tumour dataset
(GSE16515), five dysregulated pathways were identified which can
be assembled into a network based on their interactions in the
pathway interaction network constructed for this dataset. Different
colours were used to represent the five dysregulated pathways. The
common genes between pathways are differentially expressed and
the dashed line between two genes from distinct dysrugulated
pathways denotes protein-protein interaction.
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AUC scores compared with other methods on all four
datasets. For example, in GSE19027 dataset, our pathway
biomarkers got an AUC score of 0.71 compared with 0.63
by PAC biomarkers, 0.65 by BMI biomarkers and 0.52 by
gene biomarkers. Figure 3 shows the results obtained with
biomarkers identified by our method compared with the
other three methods. Furthermore, we also compared the
four methods with respect to accuracy, sensitivity and spe-
cificity. For the dataset of GSE10072, both PIN biomarkers
and PAC biomarkers achieved an AUC score of 0.99 com-
pared with 0.93 by BMI biomarkers and 0.96 by gene bio-
markers. However, PIN biomarkers achieved the highest
sensitivity and specificity. The detailed results can be
found in Additional file 2: Table S2. The good perform-
ance of our method on both training dataset and the four
independent test dataset demonstrates that our identified
dysregulated pathways can serve as robust biomarkers.
Dysregulated pathways provide insights into
pathogenesis of cancer
We further investigated the five identified dysregulated
pathways in pancreatic cancer (see Table 6). From the
pathway list, we can find that some identified dysregu-
lated pathways involve hallmark cancer genes, such as
P53, NF-κB, PI3K, etc. Figure 4 shows the interactions
among the five identified dysregulated pathways in PIN,
including P53 signaling pathway, JNK MAPK pathway,
P38 MAPK pathway, Salmonella pathway, and
CDC42RAC pathway, where the last four pathways con-
nect with each other.
P53 is a well-known tumour suppressor gene, which is
involved in various biological processes, including cell
cycle, apoptosis and senescence, etc. [36]. Mutations that
deactivate P53 were found in most tumour types, and
P53 plays an important regulation role in tumour pro-
gression. Interestingly, P53 signaling pathway was identi-
fied as the top dysregulated pathway by our method.
The JNK MAPK pathway interacts with P53 signaling
pathway. Jun N-terminal kinase (JNK) is one of
mitogen-activated protein kinase (MAPK) members and
also a stress-activated protein kinase. Both P53 and JNK
are two important apoptosis-regulatory factors fre-
quently deregulated in cancer cells. They also participate
in the modulation of autophagy and can be regulated by
TNF alpha (tumour necrosis factor alpha), which is a
soluble cytokine mediator of immune responses and
involved in various biological functions. JNK and ERK
mediate TNF alpha-induced P53 activation in apoptosis
and autophagic activity. Another identified desregulated
pathway P38 MAPK pathway is also involved in this
process, where P38 is one member of the MAPK super-
family. JNK and P38 MAPK pathways that are activated
by stress and inflammatory signals have crosstalk,thereby working together to affect proliferation, differen-
tiation, survival, and migration. The P38 MAPK pathway
can negatively regulate JNK activity in several contexts
[37]. TNF alpha regulates the JNK and P38 MAPKs in
apoptotic and autophagic process in which ERK/JNK
plays a promoting role while P38 plays an inhibiting one
[38]. JNK activation can also be negatively regulated by
NF-κB which is widely involved in oncogenesis, cell pro-
liferation and apoptosis, and evasion of immune
responses [39]. Inhibition of NF-κB activation and sus-
tained JNK activation promote the TNF alpha mediated
cell apoptotic and suppress the tumour progression [40].
The Salmonella pathway and CDC42RAC pathway are
both related to cell invasion and migration. Cdc42 gene
is the common differentially expressed gene in four dys-
regulated pathways indicating its key role in pancreatic
tumour. The CDC42RAC pathway regulates cell migra-
tion through P85 that is a subunit of PI3Ks (Phosphati-
dylinositol-3 kinases). P85 activates Cdc42 which affects
the formation of new actin fibers and interacts with
Wiskott–Aldrich syndrome protein (WASP) to stimulate
migration [41]. On the other hand, activated P85 can
bind to P110, another subunit of PI3K, which can acti-
vate Akt through PIP3 that serves as a second messen-
ger. Akt plays a main role in cell survival, proliferation,
Liu et al. BMC Bioinformatics 2012, 13:126 Page 9 of 11
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Akt have been found in some primary tumours, includ-
ing the pancreatic tumour [43].
Furthermore, we applied NOA (Network Ontology
Analysis) web tools [44] to identify enriched GO func-
tion for genes in our identified dysregulated pathways.
The top 5 enriched GO biological processes for each
pathway biomarker in pancreatic tumour dataset were
listed in Table 9. From the analysis, we found that those
enriched processes, such as regulation of cell cycle,
apoptosis and regulation of cellular component biogen-
esis, are most important biological processes in tumour
progression, thereby implying the effectiveness of our
proposed method. The identified enriched GO terms on
the other three cancer datasets were listed in Additional
file 3: Table S3.
Discussion
Identifying biomarkers in complex diseases can help
diagnose disease and design more effective drugs. The
accumulation of “omics” data, especially gene expressionTable 9 The top 5 enriched GO terms for each dysregulated p

























GO:0030833 1.5data, makes it possible to detect biomarkers in a more
efficient way [45,46]. However, it is a challenging task to
identify robust biomarkers from about 20,000 genes con-
sidering that complex diseases are usually caused from
mutations of multiple correlated genes or failure of cer-
tain subsystems rather than individual genes. Traditional
methods detecting differentially expressed genes as bio-
markers failed to work in some cases due to the inde-
pendent assumption among genes, whereas complex
diseases generally affect a set of functionally related
genes.
In this paper, we proposed a novel method to identify
dysregulated pathways in cancer. Unlike the existing
methods, our method considers the functional depend-
ency between pathways by constructing a pathway inter-
action network. Benchmarking our method on several
different cancer datasets demonstrates the effectiveness
of the proposed method. The results on independent test
datasets imply the robustness of our identified pathway
biomarkers. Further analyses indicate that the dysregu-
lated pathways that we identified are indeed involved inathway in pancreatic tumour (GSE16515) dataset
value Term name
0E-33 regulation of cell cycle
0E-22 induction of apoptosis
0E-22 induction of programmed cell death
0E-20 apoptosis
0E-20 regulation of apoptosis
0E-33 MAPKKK cascade
0E-27 signal transmission via phosphorylation event
0E-27 intracellular protein kinase cascade
0E-23 stress-activated protein kinase signaling cascade
0E-22 JNK cascade
0E-13 regulation of cellular component biogenesis
0E-13 regulation of protein complex assembly
0E-12 regulation of actin filament polymerization
0E-12 actin cytoskeleton organization
0E-12 regulation of actin polymerization or depolymerization
0E-17 phosphorus metabolic process
0E-17 phosphate metabolic process
0E-17 protein amino acid phosphorylation
0E-16 phosphorylation
0E-16 post-translational protein modification
0E-14 regulation of cellular component biogenesis
0E-12 regulation of protein complex assembly
0E-12 regulation of actin cytoskeleton organization
0E-12 regulation of actin filament-based process
0E-11 regulation of actin filament polymerization
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ways may serve as drug targets in the near future [37].
Therefore, the functional relationship between pathways
can not only provide insights into disease mechanisms
but also provide alternative ways to develop more effi-
cient drugs.
Conclusions
In this work, we present a novel approach to identify
dysregulated pathways in cancer based on a derived
pathway interaction network that describes the func-
tional dependency between pathways. The promising
results obtained by our method indicate that the dysre-
gulated pathways indeed have crosstalk with each other.
The comparison between our method and other state of
the art methods on multiple cancer datasets demon-
strates that our identified dysregulated pathways can
serve as robust biomarkers. We believe that our pro-
posed method can help to predict new biomarkers and
even drug targets in a more accurate and robust way.
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